证券日报网讯2月12日，敷尔佳（301371）在互动平台回答投资者提问时表示，截至2026年2月10日，公 司股东户数为16620户。 ...

Group 1 - The company, Fulejia (301371.SZ), stated that its directors and senior management currently have no intention to reduce their holdings [1]

Group 1 - The company, Fuhua, plans to register 48 cosmetic products by 2025, covering various forms such as water, lotion, cream, and essence [2][5] - Detailed product registration information can be found on the National Medical Products Administration website [2][5]

Core Viewpoint - The company, Fuhua, announced that it has completed the registration of two new raw materials, "Feruloyl Tripeptide-129 Amide" and "Acetyl Tyrosyl Cyclo D-Glutamyl Tripeptide-110 Amide," which are expected to enhance its product matrix by enabling further product development [1] Group 1 - The company plans to develop products based on the newly registered raw materials [1] - The registration of the new raw materials is expected to be completed by 2025 [1] - Detailed information regarding the raw material registration can be found on the National Medical Products Administration website [1]

Core Viewpoint - The company, Fuhua, is enhancing its research and development capabilities through a dual-center approach in Shanghai and Harbin, focusing on raw material development and medical device product research respectively [1] Group 1: Research and Development Strategy - The Shanghai R&D center is dedicated to raw material development and the application of cutting-edge technologies [1] - The Harbin R&D center specializes in the development of medical device products [1] - The company employs a coordinated internal and external research model, collaborating with third-party research institutions to expand diverse research directions [1] Group 2: Innovation and Competitiveness - The collaborative research focuses on efficacy validation and the application of new raw materials [1] - This internal-external synergy aims to enhance the R&D framework, balancing the autonomy and agility of technological innovation [1] - The strategy is designed to support product iteration and build long-term technological competitiveness [1]

Core Viewpoint - The company has received approval for four Class II medical device registration certificates, indicating progress in its product development and regulatory compliance [1] Group 1 - The company has obtained approval for four medical device registration certificates [1] - The approved products include: medical sodium hyaluronate repair patch, medical sodium hyaluronate repair solution, medical recombinant type III humanized collagen patch, and medical trehalose repair patch [1]

Core Viewpoint - Fuhua Jia (301371) is a specialized skin care product company focused on the research, production, and sales of professional skin care products, which are divided into medical device products and functional skin care products [1] Group 1: Product Offerings - The company's product forms include masks, waters, serums, lotions, sprays, freeze-dried products, and single-use serums [1] Group 2: Sales Strategy - The company employs an omnichannel strategy for sales, integrating both online and offline channels [1] - Online channels include major e-commerce and social media platforms such as Tmall, Douyin, JD.com, and Pinduoduo [1] - Offline channels penetrate cosmetic specialty stores, large supermarkets, chain pharmacies, beauty institutions, and medical institutions, creating a comprehensive market reach network [1]

Core Viewpoint - The company, Fuhua Jia (敷尔佳), has completed clinical trials for its recombinant type III humanized collagen freeze-dried fiber project and is preparing a summary report for registration application this year [1] Group 1 - The clinical trials for the recombinant type III humanized collagen freeze-dried fiber project have been completed [1] - The company is currently in the stage of preparing the clinical trial summary report [1] - The registration application for the project is expected to be submitted this year [1]

Group 1 - The core viewpoint of the article is that the company, Fuhua Jia (301371), has stated that its directors and senior management currently have no intention to reduce their holdings [1]

Core Viewpoint - The company, Fuhua (301371), is making progress in optimizing its offline channels, which aligns with its expectations, particularly in sales channel and retail terminal optimization [1] Group 1: Channel Optimization - The company is enhancing cooperation with service-oriented distributors through a dual approach of "strong regulation + strong optimization" to strengthen control over the offline market [1] - The focus of the strong regulation is on the meticulous management of inventory levels at agents and retail terminals to avoid stockpiling risks, while ensuring a stable pricing order through comprehensive and continuous dynamic monitoring of the pricing system across all channels [1] - The optimization aspect emphasizes the careful selection of strategic partners among agents and retail terminals, transitioning the channel model from traditional distribution to value-driven sales [1] Group 2: Future Strategies - The company aims to provide more professional and comprehensive product and service support to its partners and end consumers as part of its channel transformation strategy [1]